WO1999063928A2 - Pharmaceutical product for hemophilia and asthmatic bronchitis treatment - Google Patents
Pharmaceutical product for hemophilia and asthmatic bronchitis treatment Download PDFInfo
- Publication number
- WO1999063928A2 WO1999063928A2 PCT/BR1999/000042 BR9900042W WO9963928A2 WO 1999063928 A2 WO1999063928 A2 WO 1999063928A2 BR 9900042 W BR9900042 W BR 9900042W WO 9963928 A2 WO9963928 A2 WO 9963928A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical product
- molecular chain
- hemophilia
- glucosamine
- asthmatic bronchitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment, with effective and longstanding use, similar state-of-the-art products being unknown.
- the main objective of the present invention is to supply a pharmaceutical product for hemophilia and asthmatic bronchitis treatment that seeks to live up the suffering of the people who have these problems.
- the pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers.
- the pharmaceutical product of the present invention is a natural polymer composed by a molecular chain comprising of 5 to 850 monomers, being said polymer classified according to the set below, with its related acting ratios.
- - ⁇ -l,4-poly-N-acetyl-D-glucosamine with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 5% to 40%;
- the ratio of both chain monomers will yield the pharmaceutical product of the present invention.
- the pharmaceutical product of the present invention is useful in the treatment and the relief of internal and external bleeding of hemophilic people, and normalizes the breathing of people who suffer from asthmatic bronchitis, acting as an active ingredient for inhibiting its symptoms and effects.
- the pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is natural biologic product, in powder form, that it should be ingested orally, in the tablet form, encapsulated or mixed in the feeding. Besides its therapeutic effects, said product may be further taken as a nutritional supplement, thus allowing its customer, to improve the efficacy of some organs or glands, regardless of any disease.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment comprising a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers, being said polymer classified according to the set below, with its related acting ratios: a) β-1,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %; and b) β-1,4-poly-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %.
Description
PHARMACEUTICAL PRODUCT FOR HEMOPHILIA AND ASTHMATIC BRONCHITIS TREATMENT
The present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment, with effective and longstanding use, similar state-of-the-art products being unknown.
The researches currently developed to heal or to reduce the asthmatic bronchitis and hemophilia effects have been, in some manner, ineffective or palliative. The main objective of the present invention is to supply a pharmaceutical product for hemophilia and asthmatic bronchitis treatment that seeks to live up the suffering of the people who have these problems.
The pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers.
Preferably, the pharmaceutical product of the present invention is a natural polymer composed by a molecular chain comprising of 5 to 850 monomers, being said polymer classified according to the set below, with its related acting ratios. - β-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 5% to 40%; and
- β-l,4-poly-D-glucosamine, with a fractionated molecular chain ratio of 0% to 100%, and preferably with a fractionated molecular chain ratio of 60% to 95%.
The ratio of both chain monomers will yield the pharmaceutical product of the present invention.
The pharmaceutical product of the present invention- is useful in the treatment and the relief of internal and external bleeding of
hemophilic people, and normalizes the breathing of people who suffer from asthmatic bronchitis, acting as an active ingredient for inhibiting its symptoms and effects.
The pharmaceutical product for hemophilia and asthmatic bronchitis treatment of the present invention is natural biologic product, in powder form, that it should be ingested orally, in the tablet form, encapsulated or mixed in the feeding. Besides its therapeutic effects, said product may be further taken as a nutritional supplement, thus allowing its customer, to improve the efficacy of some organs or glands, regardless of any disease.
Claims
1. Pharmaceutical product for hemophilia and asthmatic bronchitis treatment, comprising a natural polymer of β-l,4-poly-N-acetyl- D-glucosamine and β-l,4-ρoly-D-glucosamine.
2. Pharmaceutical product as in claim 1 wherein the ratio of ╬▓-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain, is in the range 0% to 100%.
3. Pharmaceutical product as in claim 2 wherein the ratio of ╬▓-l,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain, is in the range 5% to 40%.
4. Pharmaceutical product as in claim 1 wherein the ratio of ╬▓-l,4-poly-N-glucosamine, with a fractionated molecular chain, is in the range 0% to 100%.
5. Pharmaceutical product as in claim 4 wherein the ratio of ╬▓-l,4-poly-N-glucosamine, with a fractionated molecular chain, is in the range 60% to 95%.
6. Pharmaceutical product as in claim 1 wherein said polymer is composed by a molecular chain of 1 to 5000 monomers.
7. Pharmaceutical product as in claim 6 wherein said polymer is composed by a molecular chain of 5 to 850 monomers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU45943/99A AU4594399A (en) | 1998-06-09 | 1999-06-09 | Pharmaceutical product for hemophilia and asthmatic bronchitis treatment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI9806540-8 | 1998-06-09 | ||
| BR9806540-8A BR9806540C1 (en) | 1998-06-09 | 1998-06-09 | Pharmaceutical product for the treatment of hemophilia and asthmatic bronchitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999063928A2 true WO1999063928A2 (en) | 1999-12-16 |
| WO1999063928A3 WO1999063928A3 (en) | 2000-02-03 |
Family
ID=4071490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR1999/000042 WO1999063928A2 (en) | 1998-06-09 | 1999-06-09 | Pharmaceutical product for hemophilia and asthmatic bronchitis treatment |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU4594399A (en) |
| BR (1) | BR9806540C1 (en) |
| WO (1) | WO1999063928A2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK505488D0 (en) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | MEDIUM AND USE OF SAME |
| JPH11507697A (en) * | 1995-06-09 | 1999-07-06 | エヌ． ドロハン，ウィリアム | Chitin hydrogels, their preparation and use |
| ES2231880T3 (en) * | 1996-07-29 | 2005-05-16 | Paringenix, Inc. | PROCEDURE TO TREAT ASTHMA WITH O-DESULPHATED HEPARINE. |
-
1998
- 1998-06-09 BR BR9806540-8A patent/BR9806540C1/en not_active IP Right Cessation
-
1999
- 1999-06-09 AU AU45943/99A patent/AU4594399A/en not_active Abandoned
- 1999-06-09 WO PCT/BR1999/000042 patent/WO1999063928A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| BR9806540C1 (en) | 2001-05-08 |
| WO1999063928A3 (en) | 2000-02-03 |
| AU4594399A (en) | 1999-12-30 |
| BR9806540A (en) | 2001-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhattamisra et al. | Protective activity of geraniol against acetic acid and Helicobacter pylori-induced gastric ulcers in rats | |
| CA2240161A1 (en) | Antifungal compositions with improved bioavailability | |
| BG104680A (en) | Celecoxib compositions | |
| WO2003013428A3 (en) | Nutritional supplements and methods of using same | |
| US6461646B2 (en) | Pharmaceutical composition for preventing and/or curing digestive disorders | |
| BR9906438A (en) | Nutritional reinforcement composition suitable for the treatment of pressure ulcers | |
| US20020164317A1 (en) | Cancer immune composition for prevention and treatment of individuals | |
| AU4879596A (en) | Amino acid compositions and use thereof in clinical nutrition | |
| EP0149872A2 (en) | Cosmetic composition containing glycoproteins for the skin care | |
| EP1393734A4 (en) | Drugs for intestinal diseases | |
| JO3001B1 (en) | Dietarysupplement for use in treating and/or inhibiting digestive tract ulcers | |
| AU596119B2 (en) | Appetite moderating and anti-gastritis conposition | |
| WO1996022305A3 (en) | Modified peptides | |
| WO1999063928A2 (en) | Pharmaceutical product for hemophilia and asthmatic bronchitis treatment | |
| WO1996030016A3 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
| RU2165253C2 (en) | Method of treatment of patients with oncological diseases | |
| JPWO2006038690A1 (en) | Functional food and drink | |
| US11896611B1 (en) | Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation | |
| US6824798B2 (en) | Method of preventing veisalgia | |
| CN109248255A (en) | Propolis drops canker sore is dedicated | |
| US20080145409A1 (en) | Composition for the treatment and prevention of peptic ulcer | |
| RU1826910C (en) | Biostimulating agent | |
| KR20000023968A (en) | Wild goose extract | |
| CN1268349C (en) | Water soluble medicament for anti inflammation, repressing bacteria, eliminating pes off smell and treating asjike, and its application | |
| WO2003099218A2 (en) | Anti-cancer formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |